| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $58,912,485 ) (Continued on the next page) |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA300144 | Acetylation modulates T cell receptor signaling | 000 | 1 | NIH | 6/3/2026 | $498,582 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG079859 | Therapeutic evaluation of targeting Tau Tubulin kinase-1 in Alzheimer’s disease | 001 | 4 | NIH | 2/23/2026 | $54,775 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG079859 | Therapeutic evaluation of targeting Tau Tubulin kinase-1 in Alzheimer’s disease | 000 | 4 | NIH | 12/24/2025 | $492,975 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U19AG074879 | Centrally-linked longitudinal peripheral biomarkers of AD in multi-ethnic populations | 001 | 4 | NIH | 7/21/2026 | $0 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U19AG074879 | Centrally-linked longitudinal peripheral biomarkers of AD in multi-ethnic populations | 000 | 4 | NIH | 6/11/2026 | $8,164,281 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U01AI184071 | Optimizing the diagnostic approach to cephalosporin allergy testing (DACAT Trial) | 005 | 4 | NIH | 8/18/2026 | $0 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U01AI184071 | Optimizing the diagnostic approach to cephalosporin allergy testing (DACAT Trial) | 004 | 4 | NIH | 8/8/2026 | $0 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U01AI184071 | Optimizing the diagnostic approach to cephalosporin allergy testing (DACAT Trial) | 003 | 4 | NIH | 5/7/2026 | $2,832,926 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U01AG088076 | Standardizing and Harmonizing Behavioral and Social Science Research Factors in Alzheimer's Disease through Ontology-Based Approaches | 002 | 3 | NIH | 8/20/2026 | $0 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U01AG088076 | Standardizing and Harmonizing Behavioral and Social Science Research Factors in Alzheimer's Disease through Ontology-Based Approaches | 002 | 3 | NIH | 8/20/2026 | $0 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U01AG088076 | Standardizing and Harmonizing Behavioral and Social Science Research Factors in Alzheimer's Disease through Ontology-Based Approaches | 001 | 3 | NIH | 8/12/2026 | $399,830 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U01AG088076 | Standardizing and Harmonizing Behavioral and Social Science Research Factors in Alzheimer's Disease through Ontology-Based Approaches | 001 | 3 | NIH | 8/12/2026 | $360,892 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS129671 | Tumor targeted drug delivery nanoplatform to overcome therapy resistance glioblastoma | 000 | 4 | NIH | 4/2/2026 | $618,378 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U01NS136022 | Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS (SEA-NOBI-ALS) | 001 | 3 | NIH | 7/22/2026 | $5,728,540 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R13CA290996 | Science of Community Outreach and Engagement (SoCOE) Conference | 000 | 3 | NIH | 7/14/2026 | $10,000 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | F30AG085984 | The Role of TMEM106B in FTLD-TDP Pathogenesis | 001 | 3 | NIH | 3/25/2026 | $576 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | F30AG085984 | The Role of TMEM106B in FTLD-TDP Pathogenesis | 000 | 3 | NIH | 1/16/2026 | $49,738 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG077656 | Accelerated Resolution Therapy for Early Maladaptive Grief: A Clinical Trial | 000 | 4 | NIH | 7/7/2026 | $657,515 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS137907 | Targeting Signaling Between Glioblastoma and the Subventricular Zone Niche | 000 | 3 | NIH | 8/26/2026 | $433,537 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG075802 | Investigating regional and cellular vulnerabilities to tau pathology in young-onset Alzheimer's disease | 001 | 5 | NIH | 2/23/2026 | $299,525 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG075802 | Investigating regional and cellular vulnerabilities to tau pathology in young-onset Alzheimer's disease | 000 | 5 | NIH | 12/18/2025 | $2,695,731 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA276313 | A phase I/II study of combined therapy with Th17-inducing dendritic cells and pembrolizumab in patients with recurrent epithelial ovarian cancer | 000 | 4 | NIH | 7/7/2026 | $635,464 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA266113 | Disease Progression Modeling of Bladder Cancer | 000 | 4 | NIH | 7/24/2026 | $501,455 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | UH3AG083186 | Mayo Advancing Research Engagement in ADRD Study (MAREAS Jax) | 001 | 4 | NIH | 8/24/2026 | $0 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | UH3AG083186 | Mayo Advancing Research Engagement in ADRD Study (MAREAS Jax) | 000 | 4 | NIH | 8/12/2026 | $1,145,920 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG084236 | ACTS (AD Clinical Trial Simulation): Developing Advanced Informatics Approaches for an Alzheimer's Disease Clinical Trial Simulation System | 000 | 4 | NIH | 6/25/2026 | $993,414 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | K23DK131338 | Approaches and Outcomes of Shared Decision-making and Patient Centered Care Delivery in Barrett's Esophagus | 000 | 5 | NIH | 6/8/2026 | $199,654 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01GM144393 | Exploiting new approaches for selective inhibition of trypsin-like serine proteases | 002 | 5 | NIH | 6/23/2026 | $326,840 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | U19AG069701 | Biology and Pathobiology of APOE in Aging and Alzheimer's Disease 2.0 | 004 | 6 | NIH | 8/19/2026 | $4,639,242 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | RF1NS120992 | Cryptic exons and TDP-43 neurodegeneration in Alzheimer’s and multietiology dementias | 000 | 4 | NIH | 8/14/2026 | $1,871,212 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | K23HL183845 | Breast Cancer Survivors with Obesity – Semaglutide’s Impact on Preclinical Markers of Cardiovascular Disease | 000 | 1 | NIH | 7/3/2026 | $199,244 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AT013248 | Effects of a Mobile App-Based Mindfulness Intervention in Persons with Spinal Cord Injury and Chronic Pain: A Randomized Controlled Trial | 000 | 1 | NIH | 9/1/2026 | $780,208 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | RF1NS142079 | Long-read sequencing to resolve the genomic architecture of dementia | 000 | 1 | NIH | 9/3/2026 | $1,879,248 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | RF1NS147442 | Interrogating alpha-synuclein aggregate-associated proteomes to identify modifiers of Lewy body disease. | 000 | 1 | NIH | 9/3/2026 | $1,878,189 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01DA066583 | Development of the PAIN (Pain AI iNtervention) Platform for Patients at Home | 000 | 1 | NIH | 9/3/2026 | $2,277,111 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | F32NS146048 | Decoding and Targeting the Molecular Mechanisms of TRAF7/KLF4 Driver Mutations in Meningioma | 000 | 1 | NIH | 2/24/2026 | $80,020 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS142134 | Harnessing Neurosurgery to Empower GBM-Targeted CAR-T Immunotherapies Uniquely Designed to Combat the Tumor Microenvironment” | 000 | 1 | NIH | 7/10/2026 | $599,699 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | F32NS146048 | Decoding and Targeting the Molecular Mechanisms of TRAF7/KLF4 Driver Mutations in Meningioma | 002 | 1 | NIH | 4/15/2026 | $0 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | F32NS146048 | Decoding and Targeting the Molecular Mechanisms of TRAF7/KLF4 Driver Mutations in Meningioma | 001 | 1 | NIH | 4/15/2026 | $1,260 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG082704 | Tumor susceptibility gene 101, a new microglial therapy candidate for Alzheimer’s disease to prevent cognitive decline | 000 | 2 | NIH | 8/10/2026 | $656,609 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG080556 | Role of apoE-mediated meningeal lymphatic remodeling in the pathophysiology of Alzheimer’s disease | 000 | 2 | NIH | 8/11/2026 | $767,846 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA305145 | Local Delivery of Chemotherapy to Aggressive Meningiomas using a Bioresorbable Implant | 000 | 1 | NIH | 6/23/2026 | $620,671 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | K99CA318464 | Mechanistically Guided Immunometabolic CAR-TIL Therapy for Glioblastoma Heterogeneity and Immune Suppression | 000 | 1 | NIH | 7/29/2026 | $127,983 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R35GM162590 | Hypolipoprotein Phenotyping and Evaluation of Sepsis | 000 | 1 | NIH | 7/21/2026 | $462,410 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R50CA305246 | Radiation Oncology Integration and innovation: Enhancing Lymphoma Trial Design and Establishing a Particle Therapy Research Pathway | 000 | 1 | NIH | 8/27/2026 | $163,320 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG081203 | Neuronal ABCA7 loss of function and Alzheimer’s disease | 000 | 2 | NIH | 6/19/2026 | $686,761 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01CA304198 | Senescence and Resistance in Glioblastoma | 000 | 1 | NIH | 7/10/2026 | $687,314 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01AG102578 | UFM1 as a Modifier of Tau Pathology in Alzheimer Disease and Related Tauopathies | 000 | 1 | NIH | 8/26/2026 | $522,463 |
| | 2026 | 2026 | MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION) | 4500 SAN PABLO RD S | JACKSONVILLE | FL | 32224-1865 | DUVAL | USA | R01NS147997 | Plaque morphologic characteristics that affect prevention of stroke by carotid revascularization | 000 | 1 | NIH | 5/14/2026 | $442,086 |
|
